Exploring genetic mutations linked to liver cancers and cholestatic diseases

Familial Intrahepatic Cholestasis-related Genes Associated with Disease Susceptibility in Hepato-biliary Cancers

Observational IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06777914

This study is looking to see if certain genetic changes are more common in people with liver cancers and cholestatic diseases to help understand these conditions better.

Quick facts

Study typeObservational
Enrollment600 (estimated)
Ages12 Months and up
SexAll
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other
Locations5 sites (Bologna, Bologna and 4 other locations)
Trial IDNCT06777914 on ClinicalTrials.gov

What this trial studies

This observational study aims to investigate the prevalence of genetic mutations associated with cholestatic liver diseases and hepatobiliary cancers. It involves a multicenter, cross-sectional tissue analysis where patient data, including medical history and imaging tests, will be collected. Genetic testing will be performed using a multiplex PCR NGS panel and Whole Exome Sequencing for patients with a high clinical suspicion of genetic predisposition. The study is designed to generate hypotheses for future empirical research on these conditions.

Who should consider this trial

Good fit: Ideal candidates include individuals diagnosed with hepatobiliary cancers or cholestatic liver diseases who meet specific clinical criteria.

Not a fit: Patients with documented causes of chronic liver disease unrelated to the conditions being studied may not benefit from this research.

Why it matters

Potential benefit: If successful, this study could lead to better understanding and potential early detection of genetic predispositions to hepatobiliary cancers and cholestatic liver diseases.

How similar studies have performed: While this approach is exploratory, similar studies have shown promise in identifying genetic factors associated with liver diseases.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Instrumental or histological diagnosis of HBCs, defined as primary liver and/or biliary tumors (hepatocellular carcinoma, cholangiocarcinoma, hepatocholangiocarcinoma) occurring in patients without apparent underlying chronic liver disease or in the context of cryptogenic chronic liver disease;
* Curative treatment through surgical resection of the neoplasm or liver transplantation
* Diagnosis of CCLDs defined as:

  1. GGT and/or alkaline phosphatase \>1.5 times the normal values in two or more measurements taken at least 6 months apart,
  2. A history of pruritus combined with \[BA\] \>10 mmol/l for a period of ≥6 months.
* Obtaining written informed consent

Exclusion Criteria:

* Other documented causes of chronic liver disease that can justify the clinical phenotype include:

Primary biliary cholangitis Primary sclerosing cholangitis IgG4-related cholangiopathy Obstructive jaundice excluded by the demonstration of normal bile duct anatomy Negative virological tests for HBV, HCV, HEV Alcohol abuse Hemochromatosis Wilson's disease Alpha-1 antitrypsin deficiency

Where this trial is running

Bologna, Bologna and 4 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Hepatobiliary CancersProgressive Familial Intrahepatic CholestasisCholestatic Liver Disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.